

Roger McLendon

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/12187789/roger-mclendon-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

17

papers

10,989

citations

11

h-index

17

g-index

17

ext. papers

12,419

ext. citations

17.7

avg, IF

4.58

L-index

| # | Paper | IF | Citations |
|----|--|------|-----------|
| 17 | Proteomic profiling of patient-derived glioblastoma xenografts identifies a subset with activated EGFR: implications for drug development. <i>Journal of Neurochemistry</i> , 2015 , 133, 730-8 | 6 | 10 |
| 16 | Pediatric High-Grade Gliomas and DIPG. <i>Molecular Pathology Library</i> , 2015 , 95-104 | | |
| 15 | Exomic sequencing of four rare central nervous system tumor types. <i>Oncotarget</i> , 2013 , 4, 572-83 | 3.3 | 57 |
| 14 | Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. <i>Oncotarget</i> , 2012 , 3, 709-22 | 3.3 | 439 |
| 13 | Deletion or epigenetic silencing of AJAP1 on 1p36 in glioblastoma. <i>Molecular Cancer Research</i> , 2012 , 10, 208-17 | 6.6 | 32 |
| 12 | The genetic landscape of the childhood cancer medulloblastoma. <i>Science</i> , 2011 , 331, 435-9 | 33.3 | 576 |
| 11 | Mutations in CIC and FUBP1 contribute to human oligodendrogloma. <i>Science</i> , 2011 , 333, 1453-5 | 33.3 | 399 |
| 10 | Altered telomeres in tumors with ATRX and DAXX mutations. <i>Science</i> , 2011 , 333, 425 | 33.3 | 717 |
| 9 | HDMX regulates p53 activity and confers chemoresistance to 3-bis(2-chloroethyl)-1-nitrosourea. <i>Neuro-Oncology</i> , 2010 , 12, 956-66 | 1 | 11 |
| 8 | IDH1 and IDH2 mutations in gliomas. <i>New England Journal of Medicine</i> , 2009 , 360, 765-73 | 59.2 | 4220 |
| 7 | Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma. <i>Neuro-Oncology</i> , 2008 , 10, 330-40 | 1 | 35 |
| 6 | An integrated genomic analysis of human glioblastoma multiforme. <i>Science</i> , 2008 , 321, 1807-12 | 33.3 | 4419 |
| 5 | Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma. <i>Cancer</i> , 2005 , 104, 1478-86 | 6.4 | 73 |
| 4 | Immunotherapy for gliomas91-120 | | |
| 3 | Neuropathology of gliomas146-168 | | |
| 2 | Chemotherapy for gliomas76-90 | | |
| 1 | Genetics of glioma1-23 | | 1 |

